Literature DB >> 33924475

Admission High-Sensitive Cardiac Troponin T Level Increase Is Independently Associated with Higher Mortality in Critically Ill Patients with COVID-19: A Multicenter Study.

Romaric Larcher1,2, Noemie Besnard3, Aziz Akouz4, Emmanuelle Rabier5, Lauranne Teule4, Thomas Vandercamere5, Samuel Zozor1, Matthieu Amalric3, Racim Benomar3, Vincent Brunot3, Philippe Corne3, Olivier Barbot4, Anne-Marie Dupuy1, Jean-Paul Cristol1,2, Kada Klouche2,3.   

Abstract

BACKGROUND: In coronavirus disease 2019 (COVID-19) patients, increases in high-sensitive cardiac troponin T (hs-cTnT) have been reported to be associated with worse outcomes. In the critically ill, the prognostic value of hs-cTnT, however, remains to be assessed given that most previous studies have involved a case mix of non- and severely ill COVID-19 patients.
METHODS: We conducted, from March to May 2020, in three French intensive care units (ICUs), a multicenter retrospective cohort study to assess in-hospital mortality predictability of hs-cTnT levels in COVID-19 patients.
RESULTS: 111 laboratory-confirmed COVID-19 patients (68% of male, median age 67 (58-75) years old) were included. At ICU admission, the median Charlson Index, Simplified Acute Physiology Score II, and PaO2/FiO2 were at 3 (2-5), 37 (27-48), and 140 (98-154), respectively, and the median hs-cTnT serum levels were at 16.0 (10.1-31.9) ng/L. Seventy-five patients (68%) were mechanically ventilated, 41 (37%) were treated with norepinephrine, and 17 (15%) underwent renal replacement therapy. In-hospital mortality was 29% (32/111) and was independently associated with lower PaO2/FiO2 and higher hs-cTnT serum levels.
CONCLUSIONS: At ICU admission, besides PaO2/FiO2, hs-cTnT levels may allow early risk stratification and triage in critically ill COVID-19 patients.

Entities:  

Keywords:  COVID-19; ICU; SARS-CoV-2; high-sensitive cardiac troponin T; myocardial injury; outcomes

Year:  2021        PMID: 33924475     DOI: 10.3390/jcm10081656

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  6 in total

1.  Prognostic value of the TyG index for in-hospital mortality in nondiabetic COVID-19 patients with myocardial injury.

Authors:  Halil İbrahim Biter; Muhsin Kalyoncuoğlu; Aydın Rodi Tosu; Sinem Çakal; Ziya Apaydın; Ayça Gümüşdağ; Tufan Çınar; Ferhat Eyüpkoca; Erdal Belen; Mehmet Mustafa Can
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

2.  [Myocardial Injury as a prognostic factor in Critically ill patients with Severe SARS-Cov-2 Pneumonia.]

Authors:  Christian Villavicencio; Xavier Daniel; Cristina Ferré; Marc Cartanyá; Ángel Pobo; Iban Oliva; Marina Roure; Julen Leache; María Bodí
Journal:  Med Intensiva       Date:  2022-06-13       Impact factor: 2.799

3.  Cardiac biomarkers and COVID-19: A systematic review and meta-analysis.

Authors:  Wen An; Ju-Seop Kang; Qiuyang Wang; Tae-Eun Kim
Journal:  J Infect Public Health       Date:  2021-07-29       Impact factor: 7.537

Review 4.  Use and Prognostic Implications of Cardiac Troponin in COVID-19.

Authors:  Laura De Michieli; Allan S Jaffe; Yader Sandoval
Journal:  Cardiol Clin       Date:  2022-03-31       Impact factor: 2.410

5.  The Utility of Laboratory Parameters for Cardiac Inflammation in Heart Failure Patients Hospitalized with SARS-CoV-2 Infection.

Authors:  Ciprian Nicolae Pilut; Cosmin Citu; Florin Gorun; Felix Bratosin; Oana Maria Gorun; Bogdan Burlea; Ioana Mihaela Citu; Mirela Loredana Grigoras; Diana Manolescu; Adrian Gluhovschi
Journal:  Diagnostics (Basel)       Date:  2022-03-27

Review 6.  Biomarkers in the management of acute heart failure: state of the art and role in COVID-19 era.

Authors:  Aneta Aleksova; Gianfranco Sinagra; Antonio P Beltrami; Alessandro Pierri; Federico Ferro; Milijana Janjusevic; Giulia Gagno
Journal:  ESC Heart Fail       Date:  2021-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.